Investing in Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) may appeal to individuals interested in the intersection of biotechnology and advanced computational methods.

 

Here are several reasons why someone might consider investing in the company:

1. Innovative Drug Discovery Platform: Recursion leverages artificial intelligence (AI), machine learning, and high-throughput experimentation to accelerate drug discovery and development. Their platform aims to transform traditional methods by rapidly identifying potential therapeutics across a broad range of diseases.

2. Robust and Diverse Pipeline: The company has a pipeline that includes candidates for rare genetic diseases, oncology, and inflammation. A successful approval and commercialization of any of these candidates could lead to significant revenue growth.

3. Strategic Partnerships: Recursion has established collaborations with major pharmaceutical companies like Bayer and Roche. These partnerships not only provide financial support but also validate the company's technology and approach.

4. Market Potential: By targeting diseases with high unmet medical needs, Recursion positions itself in markets with substantial growth opportunities. Success in these areas could lead to significant market share and profitability.

5. Experienced Leadership: The management team comprises experts in biotechnology, computational biology, and data science. Their combined expertise enhances the company's ability to navigate the complex landscape of drug development.

6. Cutting-Edge Technology: The integration of AI and machine learning in drug discovery is a growing trend. As an early adopter, Recursion could capitalize on advancements in computational biology, giving it a competitive edge.

7. Financial Health: The company has secured substantial funding through public offerings and private investments, providing a solid financial runway to advance its research and development efforts.

8. Intellectual Property Portfolio: A strong portfolio of patents and proprietary technologies can protect the company's competitive position and provide potential licensing opportunities.

9. Potential for High Returns: Early-stage biotech companies often offer the possibility of significant returns, especially if their drug candidates successfully reach the market.

10. Positive Industry Outlook: The biotech sector continues to grow, driven by advancements in technology and an increasing demand for innovative therapeutics.

Considerations and Risks:

• Regulatory Hurdles: Drug development involves rigorous clinical trials and regulatory approvals, which are time-consuming and expensive with no guarantee of success.
• Market Competition: The biotech field is highly competitive, with many companies vying to develop similar therapies.
• Financial Risk: Biotechnology companies often operate at a loss during their development stages and may require additional funding.
• Technological Challenges: Relying heavily on AI and machine learning introduces risks related to technological failures or limitations.

Disclaimer: Investing in biotechnology stocks involves significant risks, including the potential loss of your entire investment. This information is for educational purposes only and should not be considered financial advice. It is important to conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Often overlooked in the Ai race to enhance healthcare and medical technology, we have listed here Smallcap tech stocks with cutting edge Ai technology!

Here are ten small-cap, publicly traded companies that are incorporating cutting-edge AI technology into healthcare:

1. iCAD Inc. (NASDAQ: ICAD)

   iCAD develops advanced AI solutions for early cancer detection and therapy. Their ProFound AI® platform assists radiologists by improving the accuracy and efficiency of breast cancer detection in mammography and digital breast tomosynthesis. The technology uses deep learning algorithms to analyze images and highlight areas of concern, aiding in clinical decision-making.

2. BioXcel Therapeutics Inc. (NASDAQ: BTAI)

   BioXcel Therapeutics leverages artificial intelligence to identify and develop new medicines in neuroscience and immuno-oncology. Their proprietary AI platform, EvolverAI, analyzes vast datasets to discover novel drug candidates and repurpose existing drugs, accelerating the drug development process and reducing costs.

3. Predictive Oncology Inc. (NASDAQ: POAI)

   Predictive Oncology uses AI and machine learning to develop personalized cancer therapies. Their subsidiary, Helomics, utilizes a comprehensive tumor profiling platform powered by AI to predict how tumors will respond to various treatments. This approach aims to improve patient outcomes by tailoring therapies to individual tumor characteristics.

4. Lantern Pharma Inc. (NASDAQ: LTRN)

   Lantern Pharma employs AI-driven genomics and biomarker data to streamline the development of oncology drugs. Their proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), uses machine learning to identify patient groups most likely to benefit from specific therapies, enhancing the efficiency of clinical trials and increasing the likelihood of regulatory approval.

5. Exscientia plc (NASDAQ: EXAI)

   Exscientia is a pharmatech company specializing in AI-driven drug discovery. Their end-to-end platform integrates AI algorithms with experimental capabilities to design and optimize novel drug candidates rapidly. Exscientia has been successful in advancing multiple AI-designed molecules into clinical trials, demonstrating the potential of AI in accelerating pharmaceutical innovation.

6. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX)

   Recursion Pharmaceuticals uses AI and machine learning to accelerate drug discovery by integrating experimental biology and chemistry with advanced computational tools. Their platform rapidly identifies potential therapeutics across various disease areas, aiming to shorten the drug development timeline.

7. Renalytix plc (NASDAQ: RNLX)

   Renalytix develops AI-enabled diagnostics for kidney disease. Their KidneyIntelX™ platform uses machine learning algorithms to assess the risk of progressive decline in kidney function, aiding in early intervention and personalized treatment plans to improve patient outcomes.

8. Nanox Imaging Ltd. (NASDAQ: NNOX)

   Nanox is developing a novel digital X-ray source and AI-powered imaging systems. Their technology aims to make medical imaging more accessible and affordable globally. The integration of AI enhances image analysis, potentially enabling earlier detection of diseases.

9. Butterfly Network, Inc. (NYSE: BFLY)

   Butterfly Network has created a handheld, smartphone-connected ultrasound device powered by AI. Their Butterfly iQ+ uses AI to assist clinicians in acquiring and interpreting ultrasound images, making diagnostic imaging more accessible in various healthcare settings.

10. DarioHealth Corp. (NASDAQ: DRIO)

    DarioHealth provides digital therapeutics solutions for chronic conditions. Their AI-driven platform offers personalized health management tools for diabetes, hypertension, and weight management. By utilizing data analytics and AI, they aim to improve patient engagement and outcomes.

These companies are at the forefront of integrating artificial intelligence into healthcare, aiming to improve diagnostics, personalize treatments, and accelerate drug discovery processes. Investing in these firms involves risks typical of small-cap stocks, such as higher volatility and potential liquidity issues, so thorough due diligence is recommended.

Discl: 

We own shares of only one of these companies at this writing, however, are doing more due diligence on several others!

Two years ago! That was the last time you could buy shares of Recursion Pharmaceuticals (NASDAQ: RXRX) at today's price! Here's why!

 

Recursion Pharmaceuticals (NASDAQ: RXRX) 

recently raised approximately $200 million through a public offering of 30,769,230 shares of its Class A common stock at a price of $6.50 per share.

The lead book-running managers for this offering were Goldman Sachs & Co. LLC and J.P. Morgan, with Allen & Company LLC also acting as a book-running manager​ (Recursion Pharmaceuticals, Inc.)​​ (Market Wire News)​.

The specific buyers of these shares include institutional investors, as is typical in such offerings.

 Recursion's institutional ownership is notably high, with major investors including firms like Kinnevik AB, which holds a significant portion of shares. 

Other institutional investors involved over the last year include DNB Asset Management AS, Teachers Retirement System of the State of Kentucky, and California State Teachers Retirement System​ (Stock Market News Live | Stock Titan)​​ (MarketBeat)​.

These funds are expected to support Recursion's ongoing research and development efforts, leveraging their platform for drug discovery. This move is a strategic effort to secure additional capital necessary for advancing their clinical programs and expanding their operational capabilities​ (Recursion Pharmaceuticals, Inc.)​​ (Market Wire News)​​ (Stock Market News Live | Stock Titan)​.

also...

Nvidia owns shares in Recursion Pharmaceuticals (RXRX). 

Nvidia made a significant investment of $50 million in Recursion in July 2023, purchasing shares through a private investment in public equity (PIPE). 

As part of this investment, Nvidia acquired approximately 7.7 million shares of Recursion, which at the time was valued at $75.9 million​ (MarketBeat)​​ (Recursion Pharmaceuticals, Inc.)​​ (Ground News)​. 

This investment underscores Nvidia's confidence in Recursion's AI-driven drug discovery platform and represents a strategic partnership to leverage Nvidia's computing capabilities in the biotech field.

Financials

Recursion Pharmaceuticals is currently in a strong financial position with $296.3 million in cash and cash equivalents as of March 31, 2024 and with this recent infusion of cash, they have basically doubled their financial position.

 The company reported a revenue of $13.8 million for Q1 2024, primarily due to its partnership with Roche. However, they also posted a net loss of $91.4 million for the quarter due to significant investments in research and development and general administrative expenses. 

Technologically

Recursion continues to enhance its platform, focusing on advanced computational biology, machine learning, and transcriptomics to drive drug discovery​ (Recursion Pharmaceuticals, Inc.)​.

Discl: Long $RXRX and accumulating!

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

In Bio Science, there is a race for better Gene sequencing and genomics technology!

Investor John Templeton got his start in penny stocks. Here are some large companies that were once pennystocks!

Let’s explore how some of these tech giants 

and other companies were once penny stocks:

1. Apple (NASDAQ: AAPL): Apple, founded in 1976, had its ups and downs. With nine stock splits taken into account, it was in penny stock territory as recently as 1995. Now, it trades above $300 a share1.

2. Ford Motor Company (NYSE: F): Ford, a Fortune 500 company, was also once a penny stock. It has come a long way since then2.

3. Amazon (NASDAQ: AMZN): Believe it or not, Amazon was once a penny stock too. Its remarkable growth turned it into the e-commerce giant we know today3.

4. Google (now Alphabet): Google (now part of Alphabet) started as a penny stock when it went public in 2004. Its search engine dominance and expansion into various tech sectors transformed it into a powerhouse1.

5. Microsoft (NASDAQ: MSFT): Microsoft, with its stock splits considered, was in penny stock territory until the mid-1990s. It has since become one of the world’s most valuable companies1.

These transformations demonstrate the potential for substantial growth

even from humble beginnings!

As an interesting side note, in 1998 when Amazon was still in it's infancy, Jeff Bezos was not a multi billionaire. 

However, he saw a company that he believed had a vision for the future.  He invested $250,000 (a large sum for him at the time) into that company. That company was Google!

Bezos turned that modest $250,000 investment into $7.9 billion 

a 3 million percent-plus return

Here are five more companies that were once penny stocks that have achieved significant success:

1. Sirius XM Holdings Inc. (SIRI): Sirius XM, one of the world’s biggest audio and communication companies, was once a penny stock trading at only $0.60 about 10 years ago. It has since grown over 965% and expanded its reach with the addition of Pandora Radio1.

2. Accelerate Diagnostics Inc. (AXDX): Focused on solving antibiotic resistance challenges, Accelerate Diagnostics has seen substantial growth. Its stock was once considered a very small penny stock but has risen significantly since then1.

3. True Religion (formerly NASDAQ: TRLG): True Religion traded under $1 in the mid-2000s and grew into a strong company2.

4. Pier 1 (formerly NYSE: PIR, now OTCPK: PIRRQ): Pier 1 experienced tremendous highs as a penny stock and managed to reverse its fortunes2.

5. Monster Beverage Corporation (NASDAQ: MNST): Monster Beverage, known for energy drinks, was once a penny stock and has become a major player in the market

Remember, investing in penny stocks can be risky, but these examples show that with the right catalysts and timing, substantial growth is possible! 

Are there hidden gems in today's crop of penny stocks with new technology?

We currently own shares in these Microcap companies!

: 

DNA RXRX IONQ QBTS OUST AEVA WONDR CHPT ADPT OPEN EDIT CRSP STEM PLUG 

Recursion Pharmaceuticals is at the forefront of AI-driven drug discovery!

 Recursion Pharmaceuticals has caught the attention of major pharmaceutical companies due to its innovative approach to drug discovery. More recently, nVidia bought $70 Million of shares in $RXRX

Here’s why it’s worth knowing about:

1. AI-Driven Drug Discovery:

   Recursion collaborates with major biopharma companies to reduce research and development (R&D) costs and timelines. It employs AI-enabled methods to identify promising biological targets and molecules. By using digital chemistry and machine learning, Recursion calculates potential drug development targets efficiently.

2. Massive Data Repository:

   Recursion maintains an extensive database with over 3.1 trillion relationships between chemical and biological components. This data helps identify potential drug targets and streamline the drug discovery process.

3. Recent Acquisitions:

   Recursion recently acquired AI-related biotechs, Cyclica and Valence, which will enhance its drug discovery capabilities. These acquisitions aim to make Recursion even more effective at identifying drug targets and collaborating with pharmaceutical companies1.

4. Existing Collaborations:

    As we pointed out, powerful players like Roche and Bayer are already among Recursion’s patrons. Collaborating with Recursion allows these companies to leverage AI-driven approaches for drug discovery2.

5. Rare Disease Pipeline:

   Recursion also has its own development pipeline, including three programs in phase 2 clinical trials for rare diseases. For example, one program targets neurofibromatosis type 2, a condition affecting only 33,000 people worldwide. These pipeline projects could significantly boost Recursion’s revenue in the long term

6. Recursion Pharmaceuticals (RXRX on the Nasdaq)
7. offers a unique blend of AI-driven drug discovery, a vast data repository, and promising collaborations, making it an attractive partner for big pharmaceutical companies

Recursion Pharmaceuticals collaborates with NVIDIA to accelerate drug discovery using AI technology. Their newest supercomputer, BioHive-2, powered by 504 NVIDIA H100 Tensor Core GPUs, delivers 2 exaflops of AI performance—nearly 5x faster than their previous system.

Latest news:

Recursion Pharmaceuticals, Inc. - Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Recursion ($RXRX)

Has developed an impressive artificial intelligence system called BioHive-2, which is powered by NVIDIA AI.  

 This supercomputer is specifically designed to accelerate drug discovery in the field of biology.

 

Let me share some details about it:

1. BioHive-2: Recursion’s BioHive-2 is the largest system in the pharmaceutical industry. It’s located at Recursion’s headquarters in Salt Lake City.

   This supercomputer ranks No. 35 on the latest TOP500 list of the world’s fastest supercomputers. 

2. It’s a significant improvement over its predecessor, BioHive-1, and delivers an impressive 2 exaflops of AI performance1.

3. AI in Drug Discovery: Recursion uses AI models on BioHive-2 to accelerate drug discovery. The field of biology is incredibly complex, and finding new drug candidates often involves years of wet-lab experiments.

   Recursion’s scientists can now run over 2 million experiments per week! 

4. With AI assistance, they can focus on the most promising areas, significantly reducing the need for extensive wet lab work. The goal is to achieve 80% of the value with only 40% of the experiments, thanks to AI-guided decision-making.

5. Massive Biological Dataset: Recursion collaborates with biopharma companies like Bayer AG, Roche, and Genentech. Over time, they’ve built a 50-petabyte database containing biological, chemical, and patient data. 

6. This vast dataset fuels powerful AI models that accelerate drug discovery. In fact, Recursion believes it’s one of the largest biological datasets globally, intentionally spanning both biology and chemistry.

7. Phenom Models: Using BioHive-1, Recursion developed a family of foundation models called Phenom. These models transform microscopic cellular images into meaningful representations for understanding underlying biology. 

8. Phenom-Beta, a member of this family, is now available as a cloud API and the first third-party model on NVIDIA BioNeMo, a generative AI platform for drug discovery1.

In summary, Recursion’s AI-driven approach is revolutionizing drug discovery by leveraging massive datasets, powerful AI models, and BioHive-2’s computational prowess. 

Their work has the potential to transform our understanding of biology and improve patients’ lives through better drug treatments

Disclosure: we are long $RXRX

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases